Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
Five years after settling, GSK is again accused of breaching the Jemperli deal.
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.
And AbbVie and Genmab scoop their ASH presentation with new data.
The company adds royalty aggregation to its R&D business.
But Enhertu is coming.
